Nathan Rice

Stock Analyst at Piper Sandler

(2.86)
# 1,849
Out of 5,081 analysts
60
Total ratings
50%
Success rate
8.12%
Average return

Stocks Rated by Nathan Rice

First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49$48
Current: $38.75
Upside: +23.87%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $33.01
Upside: +27.23%
Byline Bancorp
Oct 28, 2025
Maintains: Overweight
Price Target: $34$35
Current: $28.40
Upside: +23.24%
Bank First
Oct 23, 2025
Maintains: Neutral
Price Target: $137$142
Current: $125.61
Upside: +13.05%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $77.62
Upside: -4.66%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $125.83
Upside: -33.24%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $150.93
Upside: +30.52%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $22.49
Upside: -59.98%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $732.73
Upside: -40.63%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $274.10
Upside: -14.99%
Initiates: Neutral
Price Target: $83
Current: $38.81
Upside: +113.86%
Initiates: Overweight
Price Target: $15
Current: $18.93
Upside: -20.76%